Article
Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection.
Department of Infectious Diseases, Changhai Hospital, Second Military Medical University, Shanghai, China.
BMC Gastroenterology (impact factor:
2.42).
05/2012;
12:43.
DOI:10.1186/1471-230X-12-43
pp.43
Source: PubMed
- Citations (30)
-
Cited In (0)
-
Article: Hepatitis B virus infection--natural history and clinical consequences.
New England Journal of Medicine 04/2004; 350(11):1118-29. · 53.30 Impact Factor -
Article: Global control of hepatitis B virus infection.
[show abstract] [hide abstract]
ABSTRACT: Worldwide about 350 million people are chronic carriers of the hepatitis B virus (HBV). The infection can cause acute and chronic liver disease including cirrhosis and hepatocellular carcinoma (HCC). Hepatocellular injuries of HBV infection are predominantly immune-mediated, and the natural history of chronic infection can be divided into three phases based on virus-host interactions-namely, immune tolerance, immune clearance, and viral integration phases. Four serotypes (adw, ayw, adr, and ayr) and seven genotypes (A to G) of HBV have been identified, and they show some distinct geographic distributions. The HBV genotypes may have clinical relevance and are currently under investigation. On the basis of disease burden and the availability of safe and effective vaccines, the WHO recommended that by the end of the 20th century hepatitis B vaccine be incorporated into routine infant and childhood immunisation programmes for all countries. The efficacy of universal immunisation has been shown in different countries, with striking reductions of the prevalence of HBV carriage in children. Most important, hepatitis B vaccination can protect children against HCC and fulminant hepatitis, as has been shown in Taiwan. Nevertheless, the implementation of worldwide vaccination against HBV requires greater effort to overcome the social and economic hurdles. Safe and effective antiviral treatments are available but are still far from ideal, a situation that, hopefully, will be improved soon. With hepatitis B immunisation, the global control of HBV infection is possible by the end of the first half of 21st century.The Lancet Infectious Diseases 08/2002; 2(7):395-403. · 17.39 Impact Factor -
Article: Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control.
[show abstract] [hide abstract]
ABSTRACT: To understand the role of cytotoxic T cells in liver damage and viral control, we used human histocompatibility leukocyte antigen (HLA)-peptide tetramers that allow direct ex vivo quantification of circulating and liver-infiltrating HBV-specific CD8 cells. Studies were carried out in two groups of patients, one without liver inflammation and minimal HBV replication and the other with liver damage and inflammation along with a high level of viral replication. Contrary to expectation, a high frequency of intrahepatic HBV-specific CD8 cells was found in the former group, i.e., the absence of hepatic immunopathology. In the replicating viraemic group, the virus specific T cells were diluted among the liver infiltrates; although with the massive cellular infiltration that was present, the absolute number was similar. It was also shown that in the low viraemia group the reservoir of CD8+ cells present in the circulation was able to expand after specific virus recognition and that this was not detectable in highly viraemic patients with liver inflammation. These results show that inhibition of virus replication can be independent of liver damage and when the HBV-specific CD8 response is unable to control virus replication it may contribute to liver pathology not only directly but by causing recruitment of non-virus specific T cells.Antiviral Research 11/2003; 60(2):61-6. · 4.30 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
12 asymptomatic HBV carriers
ACHBLF patients
asymptomatic HBV carriers
cell differentiation environment
chronic HBV-infected patients
chronic hepatitis B virus
cytokine levels
HBV carriers
health controls
healthy controls
interlukin-17-producing T
peripheral Th17 cells
plasm IL-17A levels
plasma HBV DNA load
serum ALT levels
Th17 cell frequency
Th17 cells
Th17 frequency
Th17 frequency(r
total bilirubin levels